Drugs / Tremfye®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07479576 Comparator | Nov 2025 → Apr 2026 overdue | — | Qilu Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tremfye | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07479576 ↗ |
| Known as | Guselkumab | “This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2106 versus Tremfye®（Guselkumab） in healthy...” NCT07479576 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT07479576 ↗ |